Targeting escape mutations
in hematological cancers
with first and best in class medicines

A small molecule oncology drug discovery company that is committed to defeating cancer.

At Eilean Therapeutics we are developing pan-variant therapies for hematologic malignancies that target the major drivers of cancer resistance, helping to overcome the limitations of current oncology therapeutics.

Targeting escape mutations
in hematological cancers
with first and best in class medicines

A small molecule oncology drug discovery company that is committed to defeating cancer.

Our Recent Publications

Eilean Therapeutics Receives Clearance To Initiate R/R AML Trial With Lomonitinib, A Selective Pan-FLT3/IRAK4 Inhibitor

Eilean Therapeutics Approved To Initiate First Patient Trial With Balamenib (Ze63-0302), A Selective Best-in-Class Menin Inhibitor

Targeting escape mutations in hematological cancerswith first and best in class medicines

A small molecule oncology drug discovery company that is committed to defeating cancer.

Our Recent Publications

Eilean Therapeutics Receives Clearance To Initiate R/R AML Trial With Lomonitinib, A Selective Pan-FLT3/IRAK4 Inhibitor

Eilean Therapeutics Approved To Initiate First Patient Trial With Balamenib (Ze63-0302), A Selective Best-in-Class Menin Inhibitor

Targeting escape mutations
in hematological cancers
with first and best in class medicines